German-based MorphoSys has a positive outlook for its antibody
producing industry, despite the research antibody segment posting
revenue 10 per cent below expectations in the six-month financial
report released today.
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
A deal has been finalised making MDS Pharma Services the preferred
contract research organization (CRO) of the Multiple Myeloma
Research Consortium (MMRC) in the US, with further opportunities in
Europe to follow.
A new drug candidate, which targets the protein that protects
cancer cells from dying, has been shown to exhibit increased
anti-tumour activity when combined with an existing cancer
treatments. The data gives hope to those who have...
Infinity Pharmaceuticals announced the initiation of a phase I
clinical trial of the company's lead investigational anticancer
agent for the development of a potential treatment for patients
with multiple myeloma. The compound...
Chiron and the multiple myeloma research consortium have announced
the initiation of a phase I clinical trial for CHIR-258 - the first
drug candidate to undergo clinical study through the MMRC - an
organisation that integrates leading...
Celgene has announced it has submitted a New Drug Application (NDA)
to the Food and Drug Administration (FDA) for its investigational
drug Revlimid, a first in a new class of novel immunomodulatory
drugs, or ImiDs.